Skip to content

Premature Umbilical Cord Blood (PUCB).

The use of autologous cord blood for anemia of prematurity.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27961
Enrollment
600
Registered
2005-09-07
Start date
2004-12-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The study population exists of prematures born after a gastational age of less than 32 weeks and 32-36 weeks with Apgar score <6, for whom at least 1 erythrocyte product is stored. The NICU is informed that this patient is a study candidate. The transfusion indications are decided by the treating physicians according to quidelines from the Dutch Society for Neonatology. In case the first transfusion is indicated the patient is randomly assigned to the autologous or an allogeneic red cell product

Interventions

Transfusion of autologous red cord blood cell concentrate vs. transfusion of stored allogeneic red blood cell concentrates.

Sponsors

Project 945-04-609 of ZonM/w Project OOPEP/1044 of Sanquin Blood supply
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pregnant women; 2. Premature (gestational age of < 36 weeks) who require a red blood cell transfusion.

Exclusion criteria

Exclusion criteria: 1. Hemolytic disease of the newborn; 2. Maternal infections such as HIV/HCV/HBV/CMV/ Toxoplasma/ Treponema pallidum or maternal septicaemia; 3. Ruptured membranes >24 hr and body temp. >38 gr. C; 4. placenta praevia, version, solutio placentae; 5. antibiotics/fungostatica < 48 hr prior to partus.

Design outcomes

Primary

MeasureTime frame
Proportion of patients who received allogeneic transfusions and the total volume of administered allogeneic red cells. Days of support of vital functions in the NICU.

Secondary

MeasureTime frame
1. Days of assisted ventilation support; 2. Cumulative complication incidence (infections, cerebral events); 3. Length of hospital stay; 4. Mortality; 5. Feasibility of erythrocyte collection from cord blood; 6. Costs of transfusions; 7. Costs of care; 8. 2 year and 5 years neurodevelopmental follow-up.

Contacts

Public ContactA. Brand

Leiden University Medical Center (LUMC), P.0. Box 2184

Anneke.Brand@bloodrtd.nl+31 (0)71 5685053

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)